Maze Therapeutics (MAZE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.70
- Surprise
- —
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target — benzinga, 2026-08-12
- Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates MAZE Sell at 5.2/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: MZE829
- Quality below floor (3.4 < 4.0)
- Momentum score 1.6/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $26.21
- Price target
- $54.41
- Stop
- $24.89
- Upside to target
- +107.6%
- Reward-to-risk
- 10.6:1
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
MAZE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.46B
- P/E (fwd)
- -8.3
- 52-week range
- $14.75–$53.65
- Off 52-week high
- 51.1%
- RSI (14)
- 41
- Volume vs avg
- 0.71×
- Score today
- 5.2/10